CDC NEWS


powered by Surfing Waves


Latest News


FDA Statement on Vaccines


26 Feb 2021

Following today’s positive advisory committee meeting outcome regarding the Janssen Biotech Inc. COVID-19 Vaccine, the U.S. Food and Drug Administration has informed the sponsor that it will rapidly work toward finalization and issuance of an emergency use authorization.


Caring for the Caregivers — Covid-19 Vaccination for Essential Members of the Health Care Team


12 Feb 2021

As U.S. states have developed guidelines for Covid-19 vaccination, some have moved to include “paid or unpaid caregivers (including parents or foster parents) of medically fragile children or adults who live at home” in Phase 1 vaccine allocation.


Necessity of 2 Doses of the Pfizer and Moderna COVID-19 Vaccines


03 Feb 2021

Two doses of the Pfizer and Moderna COVID-19 vaccines are necessary to confer adequate immunity. The new vaccines for coronavirus disease 2019 (COVID-19) are highly effective, but controversy exists about whether a second dose should be delayed in order to immunize more people. The second dose is necessary and should be given.


Did you have COVID-19? You could be reinfected by new variants


03 Feb 2021

People who already were infected with COVID-19 could face reinfection if the new coronavirus variants become the dominant strains, Dr. Anthony Fauci said Monday.


Coronavirus is in the air — there’s too much focus on surfaces


02 Feb 2021

Catching the coronavirus from surfaces is rare. The World Health Organization and national public-health agencies need to clarify their advice.




Articles


Four Vaccine Doses Prevented Severe Omicron COVID-19 Better Than 3


10 May 2022

Older patients in Israel who received a fourth dose of the BNT162b2 (Pfizer-BioNTech) SARS-CoV-2 vaccine were more than 3 times less likely to develop severe COVID-19 than those who received only 3 doses. But while protection against severe disease did not wane during the testing period, protection against confirmed infection appeared short-lived.




Rates of COVID-19 Among Unvaccinated Adults With Prior COVID-19


20 Apr 2022

Risk of SARS-CoV-2 reinfection among unvaccinated people with prior COVID-19 is a subject of debate.1,2 We performed a survival analysis in a large US population to assess the degree and duration of protection associated with natural immunity in unvaccinated individuals.




Myocarditis Adverse Event Less Common After COVID-19 Vaccine Booster


12 Apr 2022

The risk of adolescents developing myocarditis is lower after a booster dose of the BNT162b2 (Pfizer-BioNTech) COVID-19 vaccine than after the second dose, according to a CDC analysis of data from the Vaccine Adverse Event Reporting System (VAERS). Myocarditis is a rare but serious adverse event associated with COVID-19 mRNA vaccination. To assess whether this adverse event was also associated with booster doses administered to adolescents, the authors analyzed reports submitted to the VAERS system and v-safe between December 9, 2021, and February 20, 2022.




Even Mild COVID-19 May Change the Brain


23 Mar 2022

Alarge study comparing brain scans from the same individuals before and after SARS-CoV-2 infection suggests that brain changes could be a lingering outcome of even mild COVID-19. Writing in Nature, researchers at Oxford University’s Wellcome Centre for Integrative Neuroimaging reported that several months after study participants had SARS-CoV-2 infections, they had more gray matter loss and tissue abnormalities, mainly in the areas of the brain associated with smell, and more brain size shrinkage than participants who hadn’t been infected with the virus.




Risks and burdens of incident diabetes in long COVID: a cohort study


21 Mar 2022

Background There is growing evidence suggesting that beyond the acute phase of SARS-CoV-2 infection, people with COVID-19 could experience a wide range of post-acute sequelae, including diabetes. However, the risks and burdens of diabetes in the post-acute phase of the disease have not yet been comprehensively characterised. To address this knowledge gap, we aimed to examine the post-acute risk and burden of incident diabetes in people who survived the first 30 days of SARS-CoV-2 infection. Interpretation In the post-acute phase, we report increased risks and 12-month burdens of incident diabetes and antihyperglycaemic use in people with COVID-19 compared with a contemporary control group of people who were enrolled during the same period and had not contracted SARS-CoV-2, and a historical control group from a pre-pandemic era. Post-acute COVID-19 care should involve identification and management of diabetes.




Enroll for Free